Dialog Box



9:00 AM - 6:30 PM Wednesday 4th March, 2020
Perpetual Conference Room, Sydney, NSW
Registrations for this event are now closed.

This event is exclusively for doctors, clinical specialists and scientists who have an interest or are working in the field of Neurofibromatosis.


The Children's Tumour Foundation of Australia (CTF), in conjunction with Whiteley Medical is proud to present the 2020 Neurofibromatosis Symposium featuring international keynote speaker Prof. Michael J Fisher, MD from the Children's Hospital of Philadelphia (CHoP); a specialist in brain tumours and Neurofibromatosis. 

Prof. Fisher will be joined by 14 leading Australian researchers and clinicians who will provide information on the latest research, diagnosis and clinical treatments for both NF1 and NF2 patients. 

Topics covered will include, MeK Inhibitors, stem cell research, gene therapy, muscle fatigue, breast screening, non-surgical treatment of NF2, laser therapy and other treatments for skin and disfigurement as well as the latest research on the social and developmental challenges faced by most children with NF.

Date: Wednesday 4 March 2020

Location: Perpetual Conference Room, Level 18, 123 Pitt St SYDNEY

Start Time: Registrations open 9am with the first sessions commencing at 9:30am

Finish Time: 5:30pm with drinks and networking til 6:30pm

Cost: $100 per person*

* Please contact support@ctf.org.au for information about travel bursaries for those travelling interstate 



Prof. Michael J Fisher MD

Chief of Neuro-oncology, Children's Hospital of Philadelphia (CHoP), Director of the Oncology Fellowship Program, Director of the Neurofibromatosis Program at CHoP.

Prof Michael J Fisher is from the Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania. Prof Fisher is Chair of numerous international research consortia.

Prof Michael J. Fisher, MD, has a special interest in brain tumours and neurofibromatosis. He will be presenting on Optic pathway gliomas (OPGs) and how to determine treatment protocols. 

Predicting which tumours will cause vision loss could potentially revolutionise care of these patients and improve overall visual outcomes. The management of these tumours, including treatment indications, therapeutic approaches, visual assessments and potential biomarkers of vision will be discussed.


Associate Professor Yemima Berman | Head, Department of Clinical Genetics at RNSH, President Australasian Association of Clinical Geneticists, MD Research Coordinator, University of Sydney Northern Clinical School (BMBS FRACP BSc Hons PhD Medicine Clinical Geneticist (HGSA))

(speaking alongside Dr Rebecca Saunderson | Dermatologist at RNSH, NSW Faculty Honorary Secretary ACD, BMedSci (hon1) MBBS (hon) MPhil (Cantab) FACD

TOPIC: Treatment of disfigurement in NF

Associate Professor Nigel Biggs | Chairman, Department of Otolaryngology, Head and Neck and Skull Base Surgery, St Vincent's Hospital, Sydney

TOPIC: NF2 treatment options

Dr Geoffrey McCowage MB, BS, FRACP | Senior Paediatric Oncologist, Children’s Hospital Westmead 

TOPIC: MEK inhibitors in NF-1 related tumours: update and future research trials

Dr. Gautam Wali | Neuro Stem Cell Scientist, University of Sydney, The University of Sydney · Kolling Institute of Medical Research - PhD Neuroscience and Stem cell biology

TOPIC: Stem Cell Applications

Associate Professor Aaron Schindeler | Head of Bioengineering and Molecular Medicine (BAMM) Laboratory (Orthopaedic Research & Biotechnology Unit), Children's Hospital Westmead

TOPIC: Updates on L-Carnitine Therapy for NF1 and the Development of Gene Therapy Tools for NF treatment

Dr Belinda Barton | Department Head & Psychologist Children's Hospital Education Research Institute (CHERI),  NF1 Neurocognitive Research Team Leader at Kids Neuroscience Centre, Conjoint Senior Lecturer at Sydney Medical School (USYD)

TOPIC: NF Learning Clinic Learning Difficulties Studies

Dr Samantha Ginn | Senior Research Officer in the Gene Therapy Research Unit of the Children’s Medical Research Institute

TOPIC: Towards a vector-based universal genome editing approach for the treatment of Neurofibromatosis Type 1 (NF1)

Dr Katrina Morris | BMedSci MBBS (Hons) PhD FRACP, Neurologist at Royal North Shore Hospital

TOPIC: Non-surgical NF2 treatments

Dr. Jonathan Payne | DPsych, Co-Group Leader/Senior Research Fellow, Brain and Mind, Murdoch Children's Research Institute, Senior Clinical Neuropsychologist, Mental Health, The Royal Children's Hospital, Honorary Senior Fellow, Department of Paediatrics, The University of Melbourne
Murdoch Children's Research Institute

TOPIC: Social Skills and Autism Research

Matilda Wilding (RNS) and Breast Surgeon Katrina Moore

TOPIC: Breast screening in NF

Lauren Taylor/Alice Maier | Research Psychologist at MCRI

TOPIC: Severity Scale/Audiology Studies/Speech 

The goal of this symposium is to bring together researchers and clinicians with the intention of sharing current research and knowledge and improving collaboration in this diverse clinical community, that will ideally lead to improved health care for patients with this genetic disorder.

This event is proudly sponsored by